factual
Biotech in Europe struggles to raise capital
Biotech startups in Europe face particularly difficult funding because European investors are more risk averse than US investors, and Argenx survived for years on raises of no more than about $60 million.
factualpending
Speaker
JuliaEvidence Quote
“not more than $60 million before prop around for many, many years”
Created: 11/17/2026, 3:39:21 AM
Your notes
Loading notes...